Neuroinflammation pathway modulation

"Neuroinflammation pathway modulation" refers to the therapeutic targeting and regulation of molecular pathways that mediate neuroinflammatory processes in the central nervous system. These pathways include signaling cascades triggered by inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), pattern-recognition receptors (e.g., Toll-like receptors, NLRP3 inflammasome), and downstream effector mechanisms such as microglia activation, oxidative stress, and apoptosis. Pathway modulation may be achieved through small molecules, biologics (e.g., antibodies), or emerging therapies such as microglial reprogramming, with the goal of reducing detrimental neuroinflammation, protecting neural tissue, and improving outcomes in neurodegenerative and neuroinflammatory diseases. Because "neuroinflammation pathway modulation" encompasses a broad set of molecular targets and approaches, it cannot be classified as a single, distinct molecular target.

Inhibition of cytokine signaling (e.g., TNF-α, IL-1β, IL-6); Blockade of inflammatory enzyme activity (e.g., COX-2 by NSAIDs); Inhibition of inflammasome and downstream pyroptosis (e.g., Gasdermin D inhibitors); Modulation of microglial function and phenotype; Activation of pro-resolving pathways